

Datasheet for ABIN2668625
anti-NFKBIA antibody (AA 32-291)



[Go to Product page](#)

1 Image 6 Publications

Overview

Quantity:	100 µg
Target:	NFKBIA
Binding Specificity:	AA 32-291
Reactivity:	Human, Mouse
Host:	Mouse
Clonality:	Monoclonal
Conjugate:	This NFKBIA antibody is un-conjugated
Application:	Western Blotting (WB)

Product Details

Immunogen:	This IkappaBalpha antibody was raised against a recombinant protein corresponding to amino acid residues 32-291 of human IkappaBalpha.
Clone:	6A920
Isotype:	IgG1
Purification:	Affinity Purified

Target Details

Target:	NFKBIA
Alternative Name:	IkappaBalpha (NFKBIA Products)
Molecular Weight:	40 kDa

Target Details

Gene ID:	4792
Pathways:	NF-kappaB Signaling , TCR Signaling , TLR Signaling , Fc-epsilon Receptor Signaling Pathway , Activation of Innate immune Response , Cellular Response to Molecule of Bacterial Origin , Maintenance of Protein Location , Hepatitis C , Protein targeting to Nucleus , Toll-Like Receptors Cascades , BCR Signaling

Application Details

Application Notes:	Optimal working dilution should be determined by the investigator.
Restrictions:	For Research Use only

Handling

Concentration:	0.5 µg/µL
Preservative:	Sodium azide
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice:	Avoid repeated freeze/thaw cycles and keep on ice when not in storage.
Storage:	-80 °C
Storage Comment:	Antibodies in solution can be stored at -80 °C for 2 years.
Expiry Date:	6 months

Publications

Product cited in:	Blaabjerg, Christensen, Matsumoto, van der Meulen, Huising, Billestrup, Vale: "CRFR1 activation protects against cytokine-induced β-cell death." in: Journal of molecular endocrinology, Vol. 53 , Issue 3, pp. 417-27, (2014) (PubMed). Syeda, Grosjean, Houliston, Keogh, Carter, Paleolog, Wheeler-Jones: "Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways." in: The Journal of biological chemistry, Vol. 281, Issue 17, pp. 11792-804, (2006) (PubMed). Frobøse, Rønn, Heding, Mendoza, Cohen, Mandrup-Poulsen, Billestrup: "Suppressor of cytokine Signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex." in:
-------------------	---

Molecular endocrinology (Baltimore, Md.), Vol. 20, Issue 7, pp. 1587-96, (2006) ([PubMed](#)).

Jeong, Pise-Masison, Radonovich, Park, Brady: "A novel NF-kappaB pathway involving IKKbeta and p65/RelA Ser-536 phosphorylation results in p53 Inhibition in the absence of NF-kappaB transcriptional activity." in: **The Journal of biological chemistry**, Vol. 280, Issue 11, pp. 10326-32, (2005) ([PubMed](#)).

Larsen, Størling, Darville, Eizirik, Bonny, Billestrup, Mandrup-Poulsen: "Extracellular signal-regulated kinase is essential for interleukin-1-induced and nuclear factor kappaB-mediated gene expression in insulin-producing INS-1E cells." in: **Diabetologia**, Vol. 48, Issue 12, pp. 2582-90, (2005) ([PubMed](#)).

There are more publications referencing this product on: [Product page](#)

Western Blotting

Image 1. IκBα mAb tested by Western blot. The anti-IκBα detects both phosphorylated and non-phosphorylated forms of IκBα by Western blot. Jurkat cells (~1 x 10⁷) were treated for indicated time periods with 10 nm/ml PMA, 1 μM ionomycin and anti-CD28 (1:10,000 dilution). 10 μl of cytoplasmic (C) and nuclear extract (N) were resolved on a 8.75% SDS-PAGE and transferred to Immobilon membrane. Figure is courtesy of Dr. Shao-Cong Sun at Penn State Univ. College of Medicine.

